Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EB05 plus standard of care vs placebo plus standard of care in hospitalized adults with COVID-19 pneumonia
2020-006044-14Phase 3Terminated
- Sponsor
- Edesa Biotech, Inc.
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus pneumonia and coronavirus disease 2019 (COVID-19) comparing EB05 + standard of care with Placebo + standard of care (2 arms). Started Mar 2021; status: terminated.
02
Drugs
paridiprubart
03
Conditions
coronavirus pneumoniacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-006044-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006044-14.